Windtree Therapeutics
Windtree Therapeutics is a biopharmaceutical company focused on oncology and cardiovascular treatments aimed at addressing markets with significant unmet medical needs. The company develops innovative therapies such as Istaroxime for acute heart failure and cardiogenic shock, SERCA2a activators for heart failure, and oncology assets including aPKCi inhibitors. With a focus on advancing late-stage interventions, Windtree aims to improve patient outcomes in severe, acute conditions through novel and targeted therapies.
Industries
Nr. of Employees
medium (51-250)
Windtree Therapeutics
Patents
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-12343350-B2
View DetailsIstaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-11583540-B2
View DetailsIstaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-11197869-B2
View Details
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-12343350-B2
View DetailsIstaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-11583540-B2
View DetailsIstaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US-11197869-B2
View DetailsProducts
Intravenous dual-mechanism acute cardiovascular therapeutic (istaroxime)
Intravenous small-molecule therapeutic with dual mechanism intended to increase myocardial contractility via Na+/K+ ATPase inhibition and improve diastolic relaxation via SERCA2a activation; developed for acute decompensated heart failure and early cardiogenic shock.
SERCA2a activator portfolio (preclinical oral and IV candidates)
Preclinical small-molecule series designed to activate SERCA2a, including pure SERCA2a activators (no Na+/K+ pump inhibition) and dual-mechanism activators intended for oral and intravenous use in acute and chronic heart failure.
Aerosolized synthetic pulmonary surfactant and aerosol delivery system
Synthetic KL4 surfactant formulated for aerosol delivery together with a proprietary aerosol delivery system designed to generate controlled aerosols for non-invasive pulmonary administration to premature infants with respiratory distress.
Oncology kinase inhibitor program (aPKCi inhibitors)
Discovery-stage program targeting atypical protein kinase C iota with topical and oral inhibitor candidates intended for oncology indications.
Intravenous dual-mechanism acute cardiovascular therapeutic (istaroxime)
Intravenous small-molecule therapeutic with dual mechanism intended to increase myocardial contractility via Na+/K+ ATPase inhibition and improve diastolic relaxation via SERCA2a activation; developed for acute decompensated heart failure and early cardiogenic shock.
SERCA2a activator portfolio (preclinical oral and IV candidates)
Preclinical small-molecule series designed to activate SERCA2a, including pure SERCA2a activators (no Na+/K+ pump inhibition) and dual-mechanism activators intended for oral and intravenous use in acute and chronic heart failure.
Aerosolized synthetic pulmonary surfactant and aerosol delivery system
Synthetic KL4 surfactant formulated for aerosol delivery together with a proprietary aerosol delivery system designed to generate controlled aerosols for non-invasive pulmonary administration to premature infants with respiratory distress.
Oncology kinase inhibitor program (aPKCi inhibitors)
Discovery-stage program targeting atypical protein kinase C iota with topical and oral inhibitor candidates intended for oncology indications.
Services
Engagement with potential partners for strategic alliances, licensing, out-licensing and M&A to support program development.
Engagement with potential partners for strategic alliances, licensing, out-licensing and M&A to support program development.
Expertise Areas
- Clinical trial management
- Acute cardiovascular therapeutics (acute heart failure, cardiogenic shock)
- Pulmonary drug development and neonatal respiratory therapies
- Aerosol drug delivery and drug-device combination development
Key Technologies
- Aerosol drug delivery via heated-capillary aerosolization
- Synthetic pulmonary surfactant formulation
- SERCA2a activation mechanism
- Na+/K+ ATPase inhibition mechanism
News & Updates
In May 2022, Windtree reported positive results from its Phase 2 SEISMiC study of Istaroxime in early cardiogenic shock, demonstrating significant improvements in systolic blood pressure, cardiac function, and safety profile, paving the way for potential Phase 3 development.
The Phase 2b SEISMiC Part B extension study showed significant improvements in blood pressure, cardiac function, renal profile, and symptoms in patients with early cardiogenic shock, supporting further development of Istaroxime.
An overview of Windtree's focus on innovative treatments for acute cardiovascular and pulmonary syndromes, including Istaroxime and other pipeline assets.
In May 2022, Windtree reported positive results from its Phase 2 SEISMiC study of Istaroxime in early cardiogenic shock, demonstrating significant improvements in systolic blood pressure, cardiac function, and safety profile, paving the way for potential Phase 3 development.
The Phase 2b SEISMiC Part B extension study showed significant improvements in blood pressure, cardiac function, renal profile, and symptoms in patients with early cardiogenic shock, supporting further development of Istaroxime.
An overview of Windtree's focus on innovative treatments for acute cardiovascular and pulmonary syndromes, including Istaroxime and other pipeline assets.